Search Results - "Comenzo, Ray"

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis by Gertz, Morie A., Comenzo, Ray, Falk, Rodney H., Fermand, Jean Paul, Hazenberg, Bouke P., Hawkins, Philip N., Merlini, Giampaolo, Moreau, Philippe, Ronco, Pierre, Sanchorawala, Vaishali, Sezer, Orhan, Solomon, Alan, Grateau, Giles

“…We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for…”
Get full text

Responses to salvage therapy in AL amyloidosis after progression on daratumumab by Mann, Hashim, Salei, Yana, Fogaren, Teresa, Toskic, Denis, Scalia, Stephanie, Ma, Xun, Zhou, Ping, Comenzo, Ray

“…e20030 Background: Daratumumab (Dara)-based therapy is the standard for upfront treatment in systemic light-chain (AL) amyloidosis and is preferred in the…”
Get full text

Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma by Zhou, Ping, Kugelmass, Adin, Toskic, Denis, Godara, Amandeep, Fogaren, Teresa, Varga, Cindy, Comenzo, Ray

“…Abstract only 8010 Background: In systemic AL amyloidosis (AL), caused by clonal Ig free light chains (LC) produced in 75% of cases by λ clones, patients often…”
Get full text

Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement by Godara, Amandeep, Siddiqui, Nauman Saleem, Lee, Lisa, Toskic, Denis, Fogaren, Teresa, Varga, Cindy, Comenzo, Ray

“…Abstract only 8009 Background: Systemic AL amyloidosis (AL) is a rare disease in which circulating immunoglobulin light chains misfold, are directly toxic to…”
Get full text

Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial by Kastritis, Efstathios, Dispenzieri, Angela, Wechalekar, Ashutosh D., Schönland, Stefan O., Kim, Kihyun, Sanchorawala, Vaishali, Landau, Heather Jolie, Kwok, Fiona, Suzuki, Kenshi, Comenzo, Ray, Palladini, Giovanni, Berg, Deborah, Liu, Guohui, Kumar, Arun, Faller, Douglas V., Merlini, Giampaolo

“…Abstract only 8546 Background: The PI bortezomib is commonly used in first-line therapy of AL, but new therapies are needed that are tolerable in the context…”
Get full text

Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium by Lousada, Isabelle, Comenzo, Ray, Landau, Heather, Guthrie, Spencer, Merlini, Giampaolo

Get full text

Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda by Comenzo, Ray, Kastritis, Efstathios, Maurer, Mathew, Zonder, Jeffrey A., Minnema, Monique, Schönland, Stefan, Wechalekar, Ashutosh, Palladini, Giovanni, Qin, Xiang, Vasey, Sandra Y., Khan, Imran, Schecter, Jordan Mark, Merlini, Giampaolo

“…Abstract only…”
Get full text

The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction by Liedtke, Michaela, Merlini, Giampaolo, Landau, Heather Jolie, Comenzo, Ray, Seldin, David C., Weiss, Brendan M., Zonder, Jeffrey A., Walling, Jackie, Kinney, Gene, Koller, Marty, Gertz, Morie A.

“…Abstract only…”
Get full text

Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT) by Chaulagain, Chakra Pani, Ma, Xun, Doshi, Parul, Wong, Sandy Wai Kuan, Klein, Andreas Kirschmer, Sprague, Kellie A., Zhou, Ping, Comenzo, Ray

“…Abstract only…”
Get full text

Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction by Gertz, Morie A., Landau, Heather Jolie, Comenzo, Ray, Seldin, David C., Weiss, Brendan M., Zonder, Jeffrey A., Walling, Jackie, Kinney, Gene, Koller, Marty, Liedtke, Michaela

“…Abstract only…”
Get full text

NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction by Liedtke, Michaela, Landau, Heather, Comenzo, Ray, Seldin, David, Weiss, Brendan, Zonder, Jeffrey, Walling, Jackie, Kinney, Gene, Koller, Martin, Gertz, Morie A

Get full text

Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy by Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph, Arnulf, Bertrand, Kaufman, Jonathan L, Ifthikharuddin, Jainulabdeen, Weiss, Brendan M, Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Ray, Wang, Jim, Masterson, Tara, Nottage, Kerri, Schecter, Jordan, Chiu, Christopher, Khokhar, Nushmia, Ahmadi, Tahamtan, Lonial, Sagar

Get full text

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004 by Gertz, Morie A, Comenzo, Ray, Falk, Rodney H, Fermand, Jean Paul, Hazenberg, Bouke P, Hawkins, Philip N, Merlini, Giampaolo, Moreau, Philippe, Ronco, Pierre, Sanchorawala, Vaishali, Sezer, Orhan, Solomon, Alan, Grateau, Giles

“…We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for…”
Get full text

Trisomy 13q in a case of acute leukemia with lineage inconsistency by Comenzo, R, Roth, D, Desforges, J F, Berkman, E M

“…A case of acute leukemia has two distinct immature blast lines, lineage inconsistency with CD 4 positivity, and trisomy 13q as the effective cytogenetic…”
Get more information